TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04414761
Drug: GnRH Antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study: NCT01352130
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ondansetron 8 mgs
Study: NCT01352130
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Granisetron 1 mgs
Study: NCT00813566
Drug: [18F]fluoro-2-deoxy-D-glucose (FDG)
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
Study: NCT00813566
Drug: [11C]Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain scan with imaging agent to determine growth activity of tumor
Study: NCT00604123
Drug: JNJ-17166864
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
Study: NCT04167345
Drug: VX-814
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT00105300
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02711683
Drug: DL-3-n-butylphthalide
Normalized name: DL-3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Study: NCT02711683
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Study: NCT00135655
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
DrugBank: Denufosol (DB04983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003720
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03869437
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
Study: NCT03733210
Drug: Panitumumab-IRDye800
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 mg administered intravenously (IV)
Study: NCT03733210
Drug: 89-Zirconium (Zr-89) Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
Study: NCT03382314
Drug: Bazedoxifene / Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co- Administration of Bazedoxifene and Cholecalciferol
Study: NCT03792724
Drug: Urelumab + Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with intratumoral urelumab after which Nivolumab will be given.
Study: NCT00017719
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00017719
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017719
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017719
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017719
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02963311
Drug: ALN-PCSSC
Normalized name: ALN-PCSsc
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
Study: NCT00986180
Drug: NUCYNTA
Normalized name: Nucynta
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
Study: NCT00986180
Drug: Oxycodone IR
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
Study: NCT03915366
Drug: Valganciclovir Oral Solution [Valcyte]
Normalized name: valganciclovir Oral Solution [Valcyte]
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for CMV
Study: NCT02771795
Drug: Herceptin (trastuzumab)
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration
Study: NCT02771795
Drug: SB3 (proposed trastuzumab biosimilar)
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration
Study: NCT02244918
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
Study: NCT00467636
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
Study: NCT00823121
Drug: buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
Study: NCT00823121
Drug: human chorionic gonadotropin (pregnyl)
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
Study: NCT01031459
Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Normalized name: interferon beta-1b Injection [Betaseron]
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone survey of all patients.
Study: NCT00801359
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03958123
Drug: 100 μg cebranopadol
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated 100 μg cebranopadol tablet.
Study: NCT03958123
Drug: 200 μg cebranopadol
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated 200 μg cebranopadol tablet.
Study: NCT03958123
Drug: 400 μg cebranopadol
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated 400 μg cebranopadol tablet.
Study: NCT03958123
Drug: Placebo to cebranopadol encapsulated tablets
Normalized name: placebo Oral Tablet
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to cebranopadol encapsulated tablet.
Study: NCT03958123
Drug: 400 mg Moxifloxacin
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated 400 mg moxifloxacin tablet.
Study: NCT03958123
Drug: Placebo to moxifloxacin encapsulated tablets
Normalized name: placebo Oral Tablet
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
Study: NCT02340325
Drug: Acute Application of kynurenic acid cream
Normalized name: OIL OF CAMPHOR
DrugBank: Kynurenic Acid (DB11937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
Study: NCT02340325
Drug: Chronic application of kynurenic acid cream
Normalized name: OIL OF CAMPHOR
DrugBank: Kynurenic Acid (DB11937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
Study: NCT03822832
Drug: BI 655130
Normalized name: Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimer
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT00479232
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00479232
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03324932
Drug: Denosumab Injection
Normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AI intake + denosumab injection per 6 months VS only AI intake
Study: NCT00642694
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 or 20mg qd based on symptoms at patient visit
Study: NCT00642694
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 8 mg qd
Study: NCT00524498
Drug: OPC-18
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
Study: NCT00524498
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
Study: NCT00520000
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms
Study: NCT00520000
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
Study: NCT00520000
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 180mg/m2 - 340mg/m2, repeated every 21 days
Study: NCT00520000
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
Study: NCT00879892
Drug: xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas, 24 hour inhalation, en tidal target concentration 40%
Study: NCT02775474
Drug: Use of Intraoperative Intravenous Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Study: NCT00037102
Drug: interferon beta 1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04588311
Drug: Sodium Chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
Study: NCT00183937
Drug: PS 341
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
Study: NCT00183937
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
Study: NCT00244530
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04215848
Drug: Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
Study: NCT04215848
Drug: Budesonide 200Mcg Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
Study: NCT00567866
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 or 100 mg of quetiapine orally
Study: NCT01305395
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will initiate sirolimus within 6 months of heart transplant
Study: NCT01305395
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will start sirolimus after CAV has been diagnosed by angiogram
Study: NCT01305395
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
Study: NCT01305395
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will start sirolimus after they develop CAV by angiogram
Study: NCT04870138
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
Study: NCT04870138
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
Study: NCT03074773
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action
Study: NCT03074773
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: it is an amino amide local anesthetic drug
Study: NCT00270348
Drug: ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00941148
Drug: Insulin Glargin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00941148
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00941148
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin (2000 mg/day)
Study: NCT01697566
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.
Study: NCT00498901
Drug: goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00498901
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00498901
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763438
Drug: Sertindole
Normalized name: sertindole
DrugBank: Sertindole (DB06144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose
Study: NCT01406392
Drug: Misoprostol 25mcg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
Study: NCT01406392
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
Study: NCT00045539
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03386565
Drug: sodium chloride solution
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative IV infusion
Study: NCT03386565
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative IV infusion
Study: NCT03752463
Drug: DAOI-A group
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAOI with A dose
Study: NCT03752463
Drug: DAOI-C group
Normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAOI with C dose
Study: NCT02500641
Drug: Febuxostat 80/120mg/day
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
Study: NCT02500641
Drug: Allopurinol 100 up to 600mg/day
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
Study: NCT02500641
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
Study: NCT02500641
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
Study: NCT01010100
Drug: Acarbose (Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg TID
Study: NCT02194075
Drug: Fluvoxamine+Methylphenidate hydrochloride
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02194075
Drug: Fluvoxamine+sugar pill
Normalized name: fluvoxamine Pill
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02684708
Drug: cyclo, vcr, pred, dacarb,etop and doxo
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-day chemotherapy cycle
Study: NCT01062737
Drug: ASU
Normalized name: Rasuvo
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04694183
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, intravenous drip administration, d1, every 3 weeks.
Study: NCT04694183
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral, d1-14, every 3 weeks.
Study: NCT04694183
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
Study: NCT04694183
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
Study: NCT00569621
Drug: Moxaverine
Normalized name: moxaverine
DrugBank: Moxaverine (DB12251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT00826449
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 70 mg by mouth daily for 21 day cycle.
Study: NCT00826449
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg by mouth daily every 21 day cycle.
Study: NCT00005595
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02331368
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140-200 mg/m\^2